Lung Cancer Management最新文献_第3页

Lymphadenopathy and granulomas: benignancy of malignancy and differential diagnosis with endobronchial ultrasound-transbronchial needle biopsy 19G needle fine-needle aspiration biopsy. 淋巴结病变与肉芽肿:支气管内超声-经支气管穿刺活检鉴别诊断

IF 2.8

Lung Cancer Management Pub Date : 2021-05-26 eCollection Date: 2021-09-01 DOI: 10.2217/lmt-2021-0002

Paul Zarogoulidis, Dimitris Hatzibougias, Kosmas Tsakiridis, Dimitris Matthaios, Wolfgang Hohenforst-Schmidt, Haidong Huang, Chong Bai, Stavros Tryfon, Maria Saroglou, Bojan Zaric, Ioannis Boujkovinas, Chrisanthi Karapantzou

引用次数: 1

Disparities in lung cancer screening rates among the Hispanic/LatinX population. 西班牙裔/拉丁裔人群肺癌筛查率的差异

IF 2.8

Lung Cancer Management Pub Date : 2021-05-25 eCollection Date: 2021-09-01 DOI: 10.2217/lmt-2021-0004

Coral Olazagasti, Nagashree Seetharamu

引用次数: 4

HER3 expression and MEK activation in non-small-cell lung carcinoma. HER3在非小细胞肺癌中的表达和MEK的激活。

IF 2.8

Lung Cancer Management Pub Date : 2021-04-09 DOI: 10.2217/lmt-2020-0031

Thubeena Manickavasagar, Wei Yuan, Suzanne Carreira, Bora Gurel, Susana Miranda, Ana Ferreira, Mateus Crespo, Ruth Riisnaes, Chloe Baker, Mary O'Brien, Jaishree Bhosle, Sanjay Popat, Udai Banerji, Juanita Lopez, Johann de Bono, Anna Minchom

{"title":"HER3 expression and MEK activation in non-small-cell lung carcinoma.","authors":"Thubeena Manickavasagar, Wei Yuan, Suzanne Carreira, Bora Gurel, Susana Miranda, Ana Ferreira, Mateus Crespo, Ruth Riisnaes, Chloe Baker, Mary O'Brien, Jaishree Bhosle, Sanjay Popat, Udai Banerji, Juanita Lopez, Johann de Bono, Anna Minchom","doi":"10.2217/lmt-2020-0031","DOIUrl":"https://doi.org/10.2217/lmt-2020-0031","url":null,"abstract":"Aim: We explore HER3 expression in lung adenocarcinoma (adeno-NSCLC) and identify potential mechanisms of HER3 expression.Materials & methods: Tumor samples from 45 patients with adeno-NSCLC were analyzed. HER3 and HER2 expression were identified using immunohistochemistry and bioinformatic interrogation of The Cancer Genome Atlas (TCGA).Results: HER3 was highly expressed in 42.2% of cases. ERBB3 copy number did not account for HER3 overexpression. Bioinformatic analysis of TCGA demonstrated that MEK activity score (a surrogate of functional signaling) did not correlate with HER3 ligands. ERBB3 RNA expression levels were significantly correlated with MEK activity after adjusting for EGFR expression.Conclusion: HER3 expression is common and is a potential therapeutic target by virtue of frequent overexpression and functional downstream signaling.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2021-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/37/lmt-10-48.PMC8162178.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39059396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma. 晚期非小细胞肺癌患者二线治疗及以后免疫疗法的比较研究。

IF 0.9

Lung Cancer Management Pub Date : 2021-03-11 eCollection Date: 2021-09-01 DOI: 10.2217/lmt-2020-0027

Jerónimo Rafael Rodríguez-Cid, Sonia Carrasco-Cara Chards, Iván Romarico González-Espinoza, Vanessa García-Montes, Julio César Garibay-Díaz, Osvaldo Hernández-Flores, Rodrigo Riera-Sala, Anna Gozalishvili-Boncheva, Jorge Arturo Alatorre-Alexander, Luis Manuel Martínez-Barrera, Carla Paola Sánchez-Ríos, Adriana Martinez-Camacho, José Fabián Martínez-Herrera, Jordi Guzmán-Casta, Rodrigo Rafael Flores-Mariñelarena, Julián Diaz-Rico, Patricio Santillán-Doherty

{"title":"A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma.","authors":"Jerónimo Rafael Rodríguez-Cid, Sonia Carrasco-Cara Chards, Iván Romarico González-Espinoza, Vanessa García-Montes, Julio César Garibay-Díaz, Osvaldo Hernández-Flores, Rodrigo Riera-Sala, Anna Gozalishvili-Boncheva, Jorge Arturo Alatorre-Alexander, Luis Manuel Martínez-Barrera, Carla Paola Sánchez-Ríos, Adriana Martinez-Camacho, José Fabián Martínez-Herrera, Jordi Guzmán-Casta, Rodrigo Rafael Flores-Mariñelarena, Julián Diaz-Rico, Patricio Santillán-Doherty","doi":"10.2217/lmt-2020-0027","DOIUrl":"10.2217/lmt-2020-0027","url":null,"abstract":"Background: Immunotherapy has demonstrated an improved overall survival (OS) and progression-free survival (PFS) as second-line treatment and subsequent lines compared with chemotherapy.Materials & methods: This was a retrospective review among eight medical centers comprising 100 patients with a confirmed diagnosis of non-small-cell lung carcinoma, in their second-line treatment or beyond with immune checkpoints inhibitors treatment. The current study aimed to analyze effectiveness of immunotherapy in second-line treatment or further in the Mexican population, using PFS rate, OS rate and the best objective response to treatment by RECIST 1.1 as a surrogate of effectiveness.Results: In total, 100 patients met the criteria for enrollment in the current study. From the total study population, 49 patients (49.0%) were male and 51 (51.0%) were female, with an average age of 60 years and stage IV as the most prevalent clinical stage at the beginning of the study. A total of 61 patients (61.0%) had partial response; 11 (11.0%) stable disease; 2 (2.0%), complete response, 4 (4.0%), progression; and 22 (22.0%) were nonevaluable. We found a median PFS of 4 months (95% CI: 3.2-4.7 months) and an OS of 9 months (95% CI: 7.2-10.7 months).Conclusion: The response to immunotherapy is similar, with an improvement in OS and PFS, independent of which drug is used. Patients using nivolumab had a better survival, although that was not statistically significant.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2021-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/6a/lmt-10-47.PMC8369526.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39324545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database. 早期非小细胞肺癌的治疗和结果:对一家葡萄牙医院数据库的回顾性分析。

IF 2.8

Lung Cancer Management Pub Date : 2021-02-19 DOI: 10.2217/lmt-2020-0028

Marta Soares, Luís Antunes, Patrícia Redondo, Marina Borges, Ruben Hermans, Dony Patel, Fiona Grimson, Robin Munro, Carlos Chaib, Laure Lacoin, Melinda Daumont, John R Penrod, John C O'Donnell, Maria José Bento, Francisco Rocha Gonçalves

{"title":"Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database.","authors":"Marta Soares, Luís Antunes, Patrícia Redondo, Marina Borges, Ruben Hermans, Dony Patel, Fiona Grimson, Robin Munro, Carlos Chaib, Laure Lacoin, Melinda Daumont, John R Penrod, John C O'Donnell, Maria José Bento, Francisco Rocha Gonçalves","doi":"10.2217/lmt-2020-0028","DOIUrl":"https://doi.org/10.2217/lmt-2020-0028","url":null,"abstract":"Aim: This observational study evaluated treatment patterns and survival for patients with stage I-IIIA non-small-cell lung cancer (NSCLC).Materials & methods: Adults newly diagnosed with NSCLC in 2012-2016 at IPO-Porto hospital were included. Treatment data were available for patients diagnosed in 2015-2016.Results: 495 patients were included (median age: 67 years). The most common treatments were surgery alone or with another therapy (stage I: 66%) and systemic anticancer therapy plus radiotherapy (stage II: 54%; stage IIIA: 59%). One-year OS (95% CI) for patients with stage I, II and IIIA NSCLC (diagnosed 2012-2016) were 92% (88-96), 71% (62-82) and 69% (63-75), respectively; one-year OS (95% CI) for treated patients with stage I-II or stage IIIA NSCLC (diagnosed 2015-2016) were 89% (81-97) and 86% (75-98) for non-squamous cell and 76% (60-95) and 49% (34-70) for squamous cell NSCLC.Conclusion: Treatment advances are strongly needed for stage I-IIIA NSCLC, especially for patients with squamous cell histology.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2021-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/f5/lmt-10-46.PMC8162184.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39059395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Current clinical trials and patent update on lung cancer: a retrospective review. 当前肺癌的临床试验和专利更新:回顾性回顾。

IF 2.8

Lung Cancer Management Pub Date : 2021-02-15 DOI: 10.2217/lmt-2020-0029

Harshul Batra, Shrikant Pawar, Dherya Bahl

引用次数: 0

Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer. 简单的参数解决一个复杂的问题:预测肺癌对检查点抑制剂治疗的反应。

IF 2.8

Lung Cancer Management Pub Date : 2020-11-23 DOI: 10.2217/lmt-2020-0024

James Newman, Isabel Preeshagul, Nina Kohn, Craig Devoe, Nagashree Seetharamu

{"title":"Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer.","authors":"James Newman, Isabel Preeshagul, Nina Kohn, Craig Devoe, Nagashree Seetharamu","doi":"10.2217/lmt-2020-0024","DOIUrl":"https://doi.org/10.2217/lmt-2020-0024","url":null,"abstract":"Background: Noninvasive biomarkers predicting immune checkpoint inhibitor (ICI) response are urgently needed. We evaluated the predictive value of pretreatment neutrophil-to-lymphocyte ratio (NLR), smoking history, smoking intensity, BMI and programmed death ligand 1 (PD-L1) expression in non-small-cell lung cancer (NSCLC) patients treated with ICIs.Materials & methods: Single-center retrospective study included 137 patients from July 2015 to February 2018. Outcomes included 3-month disease control rate, progression-free survival, and overall survival. Predictive value of biomarkers was assessed independently and in a multivariable model.Results: NLR was associated with all outcomes. Smoking history was predictive of progression-free survival and smoking intensity was predictive of disease control rate. BMI and PD-L1 were not associated with any outcome. High BMI was associated with low NLR.Conclusion: Simple clinical biomarkers can predict response to ICIs. A score incorporating both clinical factors and established tissue/serum biomarkers may be useful in identifying NSCLC patients who would benefit from ICIs.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2020-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b2/ee/lmt-10-44.PMC8162145.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39059393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis. 酪氨酸激酶抑制剂治疗表皮生长因子受体突变晚期非小细胞肺癌的疗效和安全性:一项网络荟萃分析。

IF 2.8

Lung Cancer Management Pub Date : 2020-11-23 DOI: 10.2217/lmt-2020-0011

Abdullah Alanazi, Ismaeel Yunusa, Khaled Elenizi, Abdulaziz I Alzarea

{"title":"Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis.","authors":"Abdullah Alanazi, Ismaeel Yunusa, Khaled Elenizi, Abdulaziz I Alzarea","doi":"10.2217/lmt-2020-0011","DOIUrl":"https://doi.org/10.2217/lmt-2020-0011","url":null,"abstract":"Aim: To compare the efficacy and safety of tyrosine kinase inhibitors (TKIs) as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with positive EGFR mutation.Materials & methods: Following a systematic literature review until December 2019, we conducted a random-effects pairwise and network meta-analyses (NMA). We ranked treatments for efficacy and safety based on the surface under the cumulative ranking curve (SUCRA).Results: Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKI) improved survival outcomes with fewer grade 3 or higher adverse events compared to chemotherapy. Overall survival results suggest that osimertinib has the highest probability of being the most efficacious (SUCRA, 79.9%), followed by dacomitinib (SUCRA, 75.8%). Adverse events results suggest that osimertinib (SUCRA, 84.3%) and gefitinib (SUCRA, 78.9%) has the highest probability of being the safest.Conclusion: In this NMA, we found that osimertinib is the most efficacious and safest EGFR-TKI. These results may guide clinicians in choosing the most appropriate treatment option among EGFR-TKIs for their patient's individual clinical characteristics.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2020-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38709407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform. 间变性淋巴瘤激酶阳性非小细胞肺癌的人文生活负担:来自ALKConnect患者洞察网络和研究平台的研究结果

IF 2.8

Lung Cancer Management Pub Date : 2020-11-20 DOI: 10.2217/lmt-2020-0018

Huamao M Lin, Xiaoyun Pan, Alyssa Biller, Kyla J Covey, Hui Huang, Rebecca Sugarman, Fatima Scipione, Howard West

{"title":"Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform.","authors":"Huamao M Lin, Xiaoyun Pan, Alyssa Biller, Kyla J Covey, Hui Huang, Rebecca Sugarman, Fatima Scipione, Howard West","doi":"10.2217/lmt-2020-0018","DOIUrl":"https://doi.org/10.2217/lmt-2020-0018","url":null,"abstract":"Aim: Evaluate real-world patient preferences, experiences and outcomes (health-related quality of life [HRQoL]) from patients with anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) utilizing the ALKConnect Patient Insight Network.Patients & methods: Demographics, disease history/status/treatment, patient preferences and HRQoL (MD Anderson Symptom Inventory lung cancer module, reported as symptom severity and interference) were evaluated for US adults with ALK+ NSCLC.Results: Among 104 patients (median age: 53.0 years, 67.3% female, 40.0% employed), HRQoL and 3-month delay in disease progression were important treatment attributes. Burdensome symptoms included fatigue and disturbed sleep. Symptoms interfered most with work and day-to-day activity. Higher HRQoL was associated with ALK tyrosine kinase inhibitor (TKI) treatment and employment.Conclusion: ALKConnect demonstrated that disease progression, HRQoL, fatigue/sleep, ALK TKIs and employment matter in ALK+ NSCLC.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2020-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38709406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis and management of small pulmonary atypical carcinoid tumor associated with Cushing syndrome. 与库欣综合征相关的肺部小型非典型类癌的诊断和治疗。

IF 0.9

Lung Cancer Management Pub Date : 2020-09-14 DOI: 10.2217/lmt-2020-0010

Dathe Z Benissan-Messan, Robert E Merritt, Konstantin Shilo, Desmond M D'Souza, Peter J Kneuertz

引用次数: 0